Inicio・Lista de Acciones・MediciNova Inc

MediciNova Inc

Cerrado

SectorSanidad

1.31 1.55

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.28

Máximo

1.31

Métricas clave
By Trading Economics
Ingresos	216K -2.6M
Ventas	35K 187K
BPA	-0.05
Margen de beneficios	-1,383.144
Empleados	6
EBITDA	312K -2.5M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+501.5% upside

Dividendos
By Acuity
Próximas Ganancias	12 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-4.4M 65M
Apertura anterior	-0.24
Cierre anterior	1.31

Noticias sobre sentimiento de mercado

By Acuity

43%

57%

135 / 340 Clasificación en Healthcare

MediciNova Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

3 ago 2026, 20:06 UTC

MediciNova Inc. shares are lower, continuing a decline since Friday's close, despite positive movements in major indices like the S&P 500 and Nasdaq 100.

31 jul 2026, 19:56 UTC

Shares of MediciNova Inc. are lower during Friday's session, following a routine decline after an early high. The stock is below its 20-day moving average.

30 jul 2026, 20:51 UTC

MediciNova Inc's shares are lower in after-market hours, reflecting a broader decline in the Biotechnology sub-sector. The asset is near its one-month trading range low.

29 jul 2026, 20:09 UTC

MediciNova Inc shares are lower today, continuing a decline since Tuesday's close, and remain near their opening low amid broader market trends.

28 jul 2026, 18:46 UTC

MediciNova Inc. shares are trading higher today, remaining above Monday's close despite settling back from earlier gains during the session.

27 jul 2026, 19:06 UTC

MediciNova Inc. shares are lower today, reflecting broader market trends amid a significant decline in crude oil prices following eased geopolitical tensions.

24 jul 2026, 23:02 UTC

MediciNova Inc shares increased in after-hours trading, reflecting strong performance since Friday's close, despite mixed market sentiment and no specific company news.

23 jul 2026, 20:06 UTC

MediciNova Inc. shares are lower today, continuing a six-session decline amid routine volatility and remaining significantly below the 20-day moving average.

21 jul 2026, 19:21 UTC

MediciNova Inc. shares are lower amid no specific news, continuing a trend below the 20-day moving average over the past three sessions.

Comparación entre iguales

Cambio de precio

MediciNova Inc previsión

Precio Objetivo

By TipRanks

501.5% repunte

Estimación a 12 Meses

Media 8 USD 501.5%

Máximo 10 USD

Mínimo 6 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para MediciNova Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

Comprar

Mantener

Vender

De acuerdo con 2 analistas que ofrecen calificaciones bursátiles a para MediciNova Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

135 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de MediciNova Inc

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.